



LKT Laboratories, Inc.

SRPIN340

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lctlabs.com
Web: lctlabs.com

Product Information

Product ID S7061

CAS No. 218156-96-8

Chemical Name

Synonym SRPIN 340

Formula $C_{18}H_{18}F_3N_3O$

Formula Wt. 349.36

Melting Point


Purity $\geq 98\%$

Solubility DMSO: ≥ 42 mg/mL

Store Temp $-20^{\circ}C$

Ship Temp Ambient

Description SRPIN340 inhibits serine-arginine-rich protein kinase 1 (SRPK1), exhibiting antiviral, anti-angiogenic, and anticancer chemotherapeutic activities. In vitro, SRPIN340 inhibits replication of hepatitis C virus (HCV). In animal models of melanoma, this compound decreases expression of VEGF and suppresses tumor growth. SRPIN340 also prevents pathological retinal neovascularization in vivo.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
S7061	5 mg	\$92.90
S7061	25 mg	\$359.20

References Gammons MV, Lucas R, Dean R, et al. Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma. *Br J Cancer*. 2014 Jul 29;111(3):477-85. PMID: 25010863.

Gammons MV, Dick AD, Harper SJ, et al. SRPK1 inhibition modulates VEGF splicing to reduce pathological neovascularization in a rat model of retinopathy of prematurity. *Invest Ophthalmol Vis Sci*. 2013 Aug 27;54(8):5797-806. PMID: 23761094.

Karakama Y, Sakamoto N, Itsui Y, et al. Inhibition of hepatitis C virus replication by a specific inhibitor of serine-arginine-rich protein kinase. *Antimicrob Agents Chemother*. 2010 Aug;54(8):3179-86. PMID: 20498328.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.